問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

Recruiting Trial

1,450Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

3348Cases

2020-04-01 - 2026-09-01

Phase I/II

Active
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Healthy Volunteers and Patients with Hemophilia A

  • Condition/Disease

    Hemophilia A

  • Test Drug

    NXT007

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2023-12-01 - 2026-12-28

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2021-03-01 - 2026-12-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2024-12-30 - 2031-06-30

Phase II

Active
THE RETIRE TRIAL: A RANDOMIZED PHASE 2 TRIAL OF ADOPTIVE THERAPY WITH TREG ADOPTIVE CELL TRANSFER (TRACT) TO PREVENT REJECTION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    TRK-001

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2026-03-31

Phase II

Active
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    CVM-1118 膠囊 (又名 CVM-1118 速放膠囊 )

Participate Sites
6Sites

Recruiting6Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix’ Pertuzumab) and Perjeta® (Pertuzumab) Sourced from EU as Neoadjuvant Treatment in Combination with Trastuzumab and Chemotherapy in Patients with HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2005-12-01 - 2007-12-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-06-01 - 2027-12-31

Phase I/II

Active
Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Newly Diagnosed Glioblastoma Multiforme (GBM)

  • Test Drug

    ADI-PEG 20

Participate Sites
6Sites

Recruiting6Sites

2023-12-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

1 168 169 170 171 172 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB